CD38 and Miyoshi myopathy: Recent preclinical and early clinical data demonstrate that CAR-NK cells targeting antigens such as BCMA, SLAMF7, CD38, and GPRC5D effectively eliminate MM cells while maintaining a favorable safety profile.